Abstract
THE clinical observation of the very low incidence of peptic ulceration during pregnancy led to the finding that extracts of the urine of pregnant women had a beneficial effect on experimental ulcers in dogs1. It was later reported that not only pregnancy urine but also that from all females and males contained a potent inhibitor of gastric acid secretion2,3. Sandweiss4 named the anti-ulcer factor anthelone and regarded it as having a therapeutic effect on ulcers without depressing gastric acid secretion. The antisecretory agent was thought to be a separate entity and was called urogastrone because its actions resembled those of the postulated duodenal hormone enterogastrone5. Subsequent work amply demonstrated urogastrone action, but the existence of anthelone as a separate entity remained less well established. To establish the true nature of these agents, however, and in particular their possible role in the therapeutic control of peptic ulceration it was necessary to make a full chemical identification. Many attempts have been made to isolate urogastrone, and probably the most highly purified sample on record was that obtained by Gregory6. This was described as a combination of a golden yellow fluorescent pigment and a protein of relatively low molecular weight. Others have provided additional evidence of a protein structure7 but some recent work has led to the suggestion that urogastrone is a high-molecular weight glycoprotein8,9. Nevertheless its exact nature, source10 and physiological role have remained unknown. Gastric inhibitory effects have also been shown by extracts of animal urine but studies were undertaken on the nature of urogastrone from more readily available human urine.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sandweiss, D. J., Saltzstein, H. C., and Farbman, A., Am. J. dig. Dis., 5, 24–30 (1938).
Gray, J. S., Wieczorowski, E., and Ivy, A. C., Science, 89, 489 (1939).
Friedman, M. H. F., Rechnagel, R. O., Sandweiss, D. J., and Patterson, T. L., Proc. Soc. exp. Biol. Med., 41, 509 (1939).
Sandweiss, D. J., Gastroenterology, 1, 965 (1943).
Gray, J. C., Culmer, C. U., Wieczorowski, E., and Adkinson, J. L., Proc. Soc. exp. Biol. Med., 43, 225 (1940).
Gregory, R. A., J. Physiol., Lond., 129, 528–546 (1955).
Rosenoer, V. M., J. Physiol., Lond., 162, 173–182 (1962).
Carrea, G., Cassellato, M. M., Manera, E., Pasta, P., and Lugaro, G., Biochim. biophys. Acta, 295, 274–282 (1973).
Morimoto, T., and Yamamoto, M., J. pharmac. Soc. Japan, 89, 215–221 (1969).
Fitzgerald, J. D., Barrett, A. M., and Gregory, H., in The Physiology of Gastric Secretion (edit. by Semb, L.S., and Myren, J.), 407–411 (Oslo Universitets, Forlaget, 1968).
Gregory, H., and Willshire, I. R., UK Patent Specification No. 1394846 (1974).
Gerring, E. L., and Haworth, E., Rendic. R. Gastroenterology, 2, 167 (1970).
Gerring, E. L., thesis, Univ. London (1970).
Gerring, E. L., Bower, J., and Gregory, H., Chronic Duodenal Ulcer (edit. by Wastell, C.), 171–180 (Butterworths, London, 1974).
Gillespie, I. E., Elder, J. B., Ganguli, P. C., Gerring, E. L., and Gregory, H., Gut, 15, 337 (1974).
Elder, J. B., Ganguli, P. C., Gillespie, I. E., Delamore, I., and Gregory, H., Gut, 15, 840 (1974).
Walton, P. L., Turner, R. W., and Broadbent, D., UK Patent Specification No. 1263956 (1972).
Gregory, H., FEBS Lett., 51, 201–205 (1975).
Savage, C. R. Jr, Inagami, T., and Cohen, S., J. biol. Chem., 247, 7612–7621 (1972).
Cohen, S., J. biol. Chem., 237, 1555–1562 (1962).
Cohen, S., and Savage, C. R., Jr, Rec. Prog. Horm. Res., 30, 551–572 (1974).
Savage, C. R., Jr, and Cohen, S., J. biol. Chem., 246, 7609–7611 (1972)
Bower, J. M., Camble, R., Gregory, H., Gerring, E. L., and Willshire, I. R., Experientia (in the press).
Gregory, H., and Preston, B. M., UK Patent Application No. 39599/74.
Camble, R., Gerring, E. L., and Gregory, H., Belgian Patent No. 812973.
Atlas of Protein Sequence and Structure (edit. by Dayhoff, M. O.), (National Biomedical Research Foundation, 1972).
Mutt, V., Jorpes, J. E., and Magnusson, S., Eur J. Biochem., 15, 413–519 (1970).
Byyny, R. L., Orth, D. N., Cohen, S., and Doyne, E. S., Endocrinology, 95, 776–782 (1974).
Ances, I. G., Am. J. Obstet. Gynec., 115, 357–362 (1973).
Cohen, S., and Carpenter, G., Proc. natn. Acad. Sci. U.S.A., 72, 1317–1321 (1975).
Sandweiss, D. J., Gastroenterology, 5, 404–415 (1945).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
GREGORY, H. Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 257, 325–327 (1975). https://doi.org/10.1038/257325a0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/257325a0
This article is cited by
-
Economic optimization of expression of soluble human epidermal growth factor in Escherichia coli
Biotechnology Letters (2022)
-
In vivo evidence for the role of RegI in gastric regeneration: transgenic overexpression of RegI accelerates the healing of experimental gastric ulcers
Laboratory Investigation (2010)
-
Enhanced production of human epidermal growth factor under control of the phoA promoter by acetate-tolerant Escherichia coli DB15 in a chemically defined medium
Biotechnology and Bioprocess Engineering (2010)
-
Aryl Hydrocarbon Receptor Is an Ozone Sensor in Human Skin
Journal of Investigative Dermatology (2009)
-
Expression of Recombinant Human Epidermal Growth Factor in Escherichia coli and Characterization of its Biological Activity
Applied Biochemistry and Biotechnology (2008)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.